Publicaciones científicas

SPG11 compound mutations in spastic paraparesis with thin corpus callosum

29-jul-2008 | Revista: Neurology

L. Samaranch, PhD, M. Riverol, MD, J. C. Masdeu, MD, PhD, E. Lorenzo, BSc, J. M. Vidal-Taboada, PhD, J. Irigoyen, MSN, RN, M. A. Pastor, MD, PhD, P. de Castro, MD, PhD and P. Pastor, MD, PhD

From the Neurogenetics Laboratory, Division of Neurosciences, Center for Applied Medical Research (L.S., E.L., J.M.V.-T., J.I., P.P.), and Department of Neurology, Clínica Universitaria de Navarra (M.R., J.C.M., J.I., M.A.P., P.d.C., P.P.), University of Navarra, Pamplona, Spain.


BACKGROUND
Autosomal recessive hereditary spastic paraparesis with thin corpus callosum (ARHSP-TCC) is being increasingly recognized as a variety of spastic paraplegia with mental retardation. SPG11 gene mutations have been reported to be associated with ARHSP-TCC.

METHODS
As an independent group, we investigated SPG11 gene involvement in four individuals not previously described with either recessive or sporadic HSP-TCC presentation.

RESULTS
Chromosome 15q13-15 segregating autosomal disease haplotypes were different across the kindreds and sequencing of SPG11 identified four novel frameshift/nonsense segregating mutations and the R2034X mutation, which were in heterozygous compound status. The affected examined had decreased thalamic and bilateral paracentral frontal lobe metabolism on (18)F-flurodeoxyglucose PET.

CONCLUSIONS
Loss-of-function SPG11 mutations are the major cause of autosomal recessive hereditary spastic paraparesis with thin corpus callosum in Southern Europe, even in apparently sporadic cases. Decreased thalamic metabolism was consistently a phenotypical SPG11 mutation hallmark.

CITA DEL ARTÍCULO  Neurology. 2008 Jul 29;71(5):332-6

Nuestros autores

COVID-19